• Source: Scopus
  • Calculated based on no. of publications stored in Pure and citations from Scopus
20002020

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Dr. Nadine Hempel's research interests center on understanding molecular mechanisms that regulate metastasis and tumor recurrence of ovarian cancer, with the ultimate goal of identifying novel targets for therapy of advanced-stage disease.

Her research group uses a variety of molecular, cellular, imaging and in vivo techniques to focus on two research areas in ovarian cancer biology: first, the role of mitochondrial antioxidants and reactive oxygen species during metastatic progression; and second, the regulation of mitochondrial dynamics and metabolism in ovarian cancer.

Teaching and educational interests

Dr. Nadine Hempel is a graduate faculty member of the Biomedical Sciences Graduate Program, Clinical and Translational Science Research Training Program and MD/PhD Medical Scientist Training Program at Penn State College of Medicine.

Dr. Hempel is involved in graduate education and curricular development in her role as director of the Translational Therapeutics track in the Biomedical Sciences Graduate Program.

She is currently serving as a College of Medicine representative on Penn State's Graduate Council.

Education/Academic qualification

Postdoctoral Fellow, Albany Medical College

20072011

Postdoctoral Fellow, Duke University Medical Center

20042007

PhD, University of Queensland

… → 2004

BSc (Hons), University of Queensland

… → 1999

External positions

Council Member, Society for Redox Biology and Medicine

20142018

Fingerprint

Dive into the research topics where Nadine Hempel is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 3 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.
If you made any changes in Pure these will be visible here soon.